Forte Biosciences, Inc.
FBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $17 | $15 | $13 | $10 |
| Gross Profit | -$17 | -$15 | -$13 | -$10 |
| % Margin | – | – | – | – |
| R&D Expenses | $15,050 | $8,619 | $12,542 | $5,230 |
| G&A Expenses | $3,183 | $2,960 | $3,432 | $0 |
| SG&A Expenses | $3,183 | $2,960 | $3,432 | $2,111 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $150 | $0 | $150 | $0 |
| Operating Expenses | $18,366 | $11,564 | $16,111 | $7,341 |
| Operating Income | -$18,383 | -$11,579 | -$16,124 | -$7,351 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $701 | $330 | $468 | $196 |
| Pre-Tax Income | -$17,682 | -$11,249 | -$15,656 | -$7,155 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,682 | -$11,249 | -$15,656 | -$7,155 |
| % Margin | – | – | – | – |
| EPS | -0.99 | -0.96 | -1.37 | -1.12 |
| % Growth | -3.1% | 29.9% | -22.3% | – |
| EPS Diluted | -0.99 | -0.96 | -1.37 | -1.12 |
| Weighted Avg Shares Out | 17,794 | 11,744 | 11,399 | 6,393 |
| Weighted Avg Shares Out Dil | 17,794 | 11,744 | 11,399 | 6,393 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1,314 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $17 | $15 | $13 | $10 |
| EBITDA | -$17,665 | -$11,564 | -$16,111 | -$7,145 |
| % Margin | – | – | – | – |